Upcoming Webinar: From Small-Scale Stem Cell Production to Large-Scale hiPSC-Based Drug Development: The Flexibility of Stirred-Tank Bioreactors

20 August, 2019

Time and Date: Monday, Sept. 16, 2019 at 9am EDT | 2pm BST | 3pm CEST

Sponsor: Eppendorf and Ncardia

Register free: http://www.biopharminternational.com/bp_w/bioreactors

Stirred-tank bioreactors are gaining more and more importance in the industrial production of pharmaceutical products, biofuels and food. When compared with 2D-cultivation systems, bioreactors are easy to handle, and multiple bioreactors can be controlled in parallel without a considerable increase of workload. In stirred-tank bioreactors cells can be cultivated as free cells in solution, cell aggregates or on microcarriers in batch, fed-batch or continuous cultivation modes.

The first part of this webcast will feature a review of the basic principles of stirred-tank bioreactors. Ankita Desai of Eppendorf North America will explain factors that must be considered before and during the process, how to set up perfect conditions for cells, and how the shape of the impeller influences the stem-cell culture.

Within the second part, Arie Reijerkerk and Farbod Famili from Ncardia, a stem cell drug discovery and development company, will provide insight into how the advent of human-induced pluripotent stem cell (hiPSC) technology has substantially expanded the availability of human cells for drug discovery. The availability of these cells helps researchers to uncover the potential for better translation to the clinic and reduction of late-stage drug attrition.

Ncardia will present a case study of large-scale manufacturing development and their hiPSC-based drug screening platform, DiscoverHIT, including results from the generation of disease-relevant human stem cell-derived models and the development of predictive, phenotypic assays to enable high-throughput screening.

Key Learning Objectives:

  • Learn about the challenges and benefits of stirred-tank bioreactors
  • Receive insights on the different impeller types and their geometry on cell growth
  • Learn about the benefits and challenges of up-scaling a bioreactor process
  • Learn about the application of controlled bioreactor processes to drug discovery and development
  • Get the chance to interact with experts in a live Q&A session


Ankita Desai
Bioprocess Field Application Specialist
Eppendorf North America

Ankita Desai is a Bioprocess Field Application Specialist at Eppendorf North America. She supports customers with her expertise in cell-culture bioprocessing and applications. She holds a Master’s degree in Pharmaceutical Sciences from Northeastern University in Boston. Before joining Eppendorf North America in September 2017, Ankita has gained several experiences working for global players in the pharmaceutical industry.

Dr. Arie Reijerkerk
Head of Services and Innovation

Arie Reijerkerk is the head of services and innovation at Ncardia in Leiden, Netherlands. He holds a Master’s degree in Cell and Molecular Biology from Wageningen University and a doctorate in the field of angiogenesis and oncology from the University Medical Center Utrecht. Arie is working for Ncardia since December 2016.

Dr. Farbod Famili
Project leader assay development and high-throughput screening

Farbod Famili obtained PhD of Immunology from Leiden University Medical Center, the Netherlands. He has a strong expertise in cell-based assay development, automation and hit identification in a variety of therapeutic areas. Currently, he is scientific project leader of drug discovery and high throughput screening projects at Ncardia.